Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Bristol-Myers Squibb Co, widely known BMS- a renowned pharmaceutical company in the United States declared on September 6, 2017, that they have succeeded in testing the combination therapy and treatment to boost overall survival in patients suffering from kidney cancer. This success has helped the company to end its trial before the planned schedule, despite previous reports generated had mixed results considering other chief goals.

The company mentioned in a statement that an amalgamation of Yervoy and Opdivo, its two key medications, showed higher total survival rates compared to a standard care medication that was used to treat formerly untreated patients suffering from metastatic or advanced renal cell carcinoma. In August 2017, Bristol- Myers quoted that the amalgamated treatment failed in improving progression-free cancer survival in most of the patients. However, it was successful in decreasing the size of the cancer tumor in many patients.

Research analyst from Leerink, Seamus Fernandez had written in a client note that, “we are of a belief that the total survival advantage is most likely to confirm the durability of the indication noticed on progression-free survival, thus resulting in an extremely high likelihood of medication approval.” As per the information given by Cowen and Co, the trials to gauge the complete survival rates are expected to be executed during the second half of 2019. Bristol-Myers added that the trail was ended before time after the results of a planned interim analysis were successful. This also helped the company shares to went up by 4.2 percent and reach a 52-week high amounting to US$ 62.415 this time.
The shares of Exelixis Inc- a rival pharmaceutical company which is in process of manufacturing a competitive treatment for kidney cancer, dropped down by 10 percent. In addition, trial results of Bristol-Myers increased hopes and expectations for lung cancer therapy from AstraZeneca Plc that failed to deliver progression-free survival in July.

You may be interested

Widespread Use Of Insulin Pens Is Likely To Fuel The Growth Of The Disposable Insulin Pen Market
Healthcare
Healthcare

Widespread Use Of Insulin Pens Is Likely To Fuel The Growth Of The Disposable Insulin Pen Market

Mohit Joshi - October 20, 2018

The Disposable Insulin Pen Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released by Coherent Market Insights, added in its…

Pulse Oximeter Market Is Also Driven By Technology Advancements And Also In Expansion Of Clinical Applications
Healthcare
Healthcare

Pulse Oximeter Market Is Also Driven By Technology Advancements And Also In Expansion Of Clinical Applications

Mohit Joshi - October 20, 2018

The Pulse Oximeter Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released by Coherent Market Insights, added in its large…

Extracorporeal Shock Wave Lithotripsy Market Is Being Fuelled By Rise In Incidence Of Kidney Stones
Healthcare
Healthcare

Extracorporeal Shock Wave Lithotripsy Market Is Being Fuelled By Rise In Incidence Of Kidney Stones

Mohit Joshi - October 20, 2018

The Extracorporeal Shock Wave Lithotripsy Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released by Coherent Market Insights, added in…

Most from this category